To the full analysis
Sinopharm Group stock: growth
1099.HKSinopharm Group reported $86.25B in revenue for fiscal 2025, down 1.6% on the prior year, up 4.7% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
18.3%
per year from 2006 to 2025, per share 14.3%
Earnings (Annual rate)
21.3%
per year from 2006 to 2025, per share 21.1%
Free cash flow (Annual rate)
20.2%
per year from 2006 to 2025, per share 16.2%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 4.7% | 9.7% | 18.3% |
| Revenue per share | 4.7% | 8.4% | 14.3% |
| Earnings | −0.1% | 6.6% | 21.3% |
| Earnings per share | −0.2% | 5.3% | 21.1% |
| Free cash flow | 6.7% | 0.1% | 20.2% |
| Free cash flow per share | 6.6% | −1.1% | 16.2% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $3.56B | $27.36M | $56.75M |
| 2007 | $4.67B | $80.37M | $27.15M |
| 2008 | $5.73B | $122.69M | $52.17M |
| 2009 | $7.06B | $126.84M | $91.96M |
| 2010 | $10.38B | $181.27M | −$49.23M |
| 2011 | $15.33B | $234.03M | −$16.54M |
| 2012 | $20.36B | $296M | $374.6M |
| 2013 | $25.02B | $337.42M | $571.82M |
| 2014 | $30.01B | $431.12M | $616.4M |
| 2015 | $34.29B | $563.96M | $1.86B |
| 2016 | $38.71B | $696.93M | $1.18B |
| 2017 | $41.54B | $1.18B | −$34.09M |
| 2018 | $51.67B | $1.41B | $37.43M |
| 2019 | $63.78B | $1.59B | $2.43B |
| 2020 | $68.45B | $1.08B | $1.36B |
| 2021 | $78.14B | $1.16B | $1.06B |
| 2022 | $82.8B | $1.28B | $2.78B |
| 2023 | $89.46B | $1.36B | $2.23B |
| 2024 | $87.66B | $1.06B | $1.44B |
| 2025 | $86.25B | $1.07B | $1.88B |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = HK$7.8782, $1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 30 Sep 2016)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.